Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02164955
Recruitment Status : Active, not recruiting
First Posted : June 17, 2014
Last Update Posted : July 17, 2019
Sponsor:
Information provided by (Responsible Party):
Celgene

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : August 31, 2022
Estimated Study Completion Date : August 31, 2022